Current and Complete Phase II bTrials
|
Study |
Title | Principal Investigator | Study Coordinator | Funder & Sponsor | Publications |
|
115616 (TUBERCULOSIS-018) [M72/AS01E (GSK692342)] |
A phase IIb, double-blind, randomised, placebocontrolled study to evaluate the efficacy, safety and immunogenicity of GSK Biologicals’ candidate tuberculosis (TB) vaccine GSK 692342 against TB disease, in adults aged 18-50 years, living in a TB endemic region. |
PI: Assoc Prof Mark Hatherill Sub Investigator: Dr Michelle Tameris |
D. van As | Sponsor: Aeras |
| Study | Title | Principal Investigator | Study Coordinator | Funders | Publication |
|
AERAS 485)C-020-485(MVA85A/ |
Phase II Double-blinded Randomized Controlled Evaluation of MVA85A/AERAS-485 for Safety, Immunogenicity and Prevention of Tuberculosis in BCG-Vaccinated, HIV-negative Infants | Dr Michele Tameris | L.v d Merwe | Partners: Aeras Global TB Vaccine Foundation, Oxford University, Emergent BioSolutions, Isis Innovation Ltd | The Lancet Volume 381. |
SATVI Worcester Site Office:
SATVI Project Office, University of Cape Town, Brewelskloof Hospital, Haarlem Street, WORCESTER, 6850.
Tel: +27 23 346 5400
Fax: +27 23 346 5406
Email: Field Site Manager
GPS coordinates -33.620455, 19.458576
Map to Worcester Field Office